Financial Performance - For the three months ended June 30, 2021, the company reported total revenue of HKD 13,646,000, an increase of 31.8% compared to HKD 10,372,000 for the same period in 2020[4] - The profit attributable to the owners of the company for the first quarter was HKD 1,509,000, representing a 72.8% increase from HKD 873,000 in the previous year[4] - Basic and diluted earnings per share for the quarter were both HKD 0.38, up from HKD 0.18 in the same quarter of the previous year[5] - The company recorded a total comprehensive income of HKD 1,494,000 for the quarter, compared to HKD 888,000 in the previous year[4] - The company's revenue for the three months ended June 30, 2021, increased by HKD 3.2 million or 30.8% to HKD 13.6 million compared to the same period in 2020[32] - The profit attributable to the company's owners increased by 66.7% to HKD 1.5 million from HKD 0.9 million in the same period last year[34] - Basic earnings per share for the period were HKD 0.38, compared to HKD 0.18 in the previous year[34] - The net profit attributable to the company's owners rose by HKD 0.6 million or 66.7% from HKD 0.9 million to HKD 1.5 million for the three months ended June 30, 2021[46] Revenue Breakdown - Revenue from medical consultation services was HKD 343,000, an increase of 20.8% from HKD 284,000 in the prior year[12] - Revenue from prescription and dispensing services was HKD 2,354,000, a slight increase of 5.1% compared to HKD 2,240,000 in the previous year[12] - Revenue from treatment services surged to HKD 10,949,000, a significant increase of 39.5% from HKD 7,848,000 in the same quarter of 2020[12] - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.5%, 17.3%, and 80.2% of total revenue, respectively[32] Assets and Liabilities - The company’s total assets as of June 30, 2021, were HKD 19,991,000, reflecting a decrease from HKD 30,401,000 as of June 30, 2020[7] - The cost of used inventory for the three months ended June 30, 2021, was HKD 2.2 million, representing 16.3% of the related period's revenue[39] - Employee costs increased by HKD 0.9 million or 19.1% from HKD 4.7 million to HKD 5.6 million, attributed to higher salaries and performance bonuses due to increased revenue[40] Business Strategy and Future Plans - The company plans to continue focusing on expanding its medical consultation and treatment services to drive future growth[10] - The group plans to continue introducing new services and products to drive business growth and maintain competitiveness in the industry[35] - The group aims to maximize revenue and improve operational efficiency despite ongoing challenges from the COVID-19 pandemic[35] - The group will continue to seek new business opportunities to enhance its brand and provide maximum returns to investors[35] Compliance and Governance - The board confirmed that the financial statements were prepared in accordance with the Hong Kong Financial Reporting Standards, ensuring compliance and accuracy[9] - The audit committee, consisting of three independent non-executive directors, reviewed the group's financial statements and confirmed compliance with applicable accounting standards and regulations[64] Special Events and Other Information - The company declared a special dividend of HKD 0.025 per share, totaling HKD 9,918,000, which was distributed on July 26, 2021[22] - The company has implemented video consultation services and delivery for skincare and certain medications in response to the adverse economic conditions due to the COVID-19 pandemic[31] - The company received government subsidies related to the COVID-19 pandemic, which included commitments to retain employees during the subsidy period[18] - The group has entered into a lease agreement for a property in Hong Kong, with a right-of-use asset recognized at HKD 6.9 million[47] - As of June 30, 2021, Dr. Jiang holds a controlling interest in 274,865,400 shares, representing 69.28% of the issued share capital[49] - The company did not purchase, sell, or redeem any of its listed securities during the three months ended June 30, 2021[61] - As of June 30, 2021, there were a total of 4,000,000 unexercised share options, all of which were vested and could be issued as ordinary shares[63]
密迪斯肌(08307) - 2022 Q1 - 季度财报